Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 5/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6885814 | 0.83 | PRMT5 (0.46) | PRMT5ENPP2 | |
| SCHEMBL1643515 | 0.81 | FFAR1 (0.46) | RAB9AMEN1NPC1KMT2ADRD2 | |
| SCHEMBL6885909 | 0.78 | ENPP2 (0.43) | PRMT5ENPP2 | |
| SCHEMBL7359344 | 0.75 | DRD2 (0.50) | ROCK2RAB9AMEN1NPC1KMT2A | |
| SCHEMBL6888436 | 0.75 | FAAH (0.45) | HDAC1ENPP2 | |
| SCHEMBL6886663 | 0.75 | L3MBTL1 (0.55) | MEN1NPC1KMT2APRMT5ENPP2 | |
| Hydrochloric Acid SCHEMBL8389936 | 0.74 | DRD2 (0.49) | ROCK2RAB9AMEN1NPC1KMT2A | |
| SCHEMBL6886805 | 0.73 | GRM2 (0.43) | PRMT5EGLN1ENPP2 | |
| SCHEMBL6885751 | 0.73 | GRIN1 (0.47) | ENPP2 | |
| SCHEMBL6886132 | 0.73 | ENPP2 (0.41) | RAB9AMEN1NPC1KMT2APRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389536-B2 | Positive allosteric modulators (PAM) | HOFFMANN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20110098313-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | HOFFMANN-LA ROCHE, INC. | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098313-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | GRM5, GRM1, GRM2 | ROCK2 3279/4885RAB9A 2271/4885MEN1 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.